AlphaCrest Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-82,063
Closed -$3.59M 837
2022
Q3
$3.59M Sell
82,063
-7,292
-8% -$354K 0.22% 64
2022
Q2
$4.68M Sell
89,355
-125,963
-59% -$6.42M 0.23% 78
2022
Q1
$11.1M Buy
215,318
+81,493
+61% +$4.23M 0.62% 13
2021
Q4
$7.9M Sell
133,825
-24,832
-16% -$1.23M 0.29% 44
2021
Q3
$6.82M Sell
158,657
-211,036
-57% -$9.35M 0.35% 25
2021
Q2
$14.5M Buy
369,693
+215,430
+140% +$8.38M 0.62% 4
2021
Q1
$5.59M Sell
154,263
-157,731
-51% -$5.6M 0.31% 53
2020
Q4
$11.5M Buy
311,994
+298,116
+2,148% +$10.9M 0.95% 3
2020
Q3
$483K Sell
13,878
-114,136
-89% -$4M 0.05% 608
2020
Q2
$3.97M Buy
128,014
+110,886
+647% +$3.77M 0.66% 11
2020
Q1
$530K Sell
17,128
-197,994
-92% -$6.75M 0.06% 542
2019
Q4
$8M Buy
215,122
+25,886
+14% +$922K 0.66% 5
2019
Q3
$6.45M Buy
189,236
+113,427
+150% +$4.12M 0.39% 15
2019
Q2
$3.12M Buy
75,809
+29,944
+65% +$1.19M 0.27% 62
2019
Q1
$1.85M Buy
45,865
+32,199
+236% +$1.29M 0.28% 55
2018
Q4
$566K Buy
+13,666
New +$567K 0.17% 198

Other funds holding PFE

AlphaCrest Capital Management's PFE Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Pfizer (PFE) in Q4 2022, closing a stake of 82,063 shares — an estimated $3.59M sold.

AlphaCrest Capital Management first reported a position in PFE in Q4 2018 and held it in 16 quarters. The position peaked at $14.5M in Q2 2021. 3,265 funds tracked by Wall St. Rank hold PFE as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Pfizer position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 82,063 Pfizer shares in Q4 2022, an estimated $3.59M.
  • AlphaCrest Capital Management first reported a position in Pfizer in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's Pfizer position peaked at $14.5M in Q2 2021.
  • 3,265 funds tracked by Wall St. Rank held Pfizer as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.